Chongqing Zhifei Biological Products News

Research Nuggets丨Tianfeng Securities: Maintaining Zhifei Biotech's “Buy” Rating and Sales of Recombinant Herpes Vaccine Is Worth Looking Forward to

Gelonghui FinanceMay 23 15:49

Zhifei Biotech (300122): Steady growth in recombinant shingles vaccine sales in 2023 is worth looking forward to

天風證券May 22 18:26

Research Report Nuggets丨CITIC Construction Investment: Zhifei Biotech's shingles vaccine contributed new volume and maintained a “buy” rating

Gelonghui FinanceMay 9 15:49

Zhifei Biotech (300122): The existing business is steady and far reaching new contributions to the shingles vaccine

中信建投證券May 9 11:26

Zhifei Biotech (300122): HPV vaccine enters steady growth period, focus on shingles vaccine dosage

中金公司May 8 08:11

Zhifei Biotech (300122): Performance during the reporting period was slightly lower than expected, “Self-developed & Agency” dual-drive built a long-term growth engine for performance

方正證券Apr 30 13:26

Zhifei Biotech (300122): Nine valent HPV accelerates the release of shingles and opens up room for growth

西部證券Apr 30 00:00

Zhifei Biotech (300122): HPV vaccine continuous release development pipeline enters harvest period

廣發證券Apr 29 18:46

Zhifei Biotech (300122): Further release of the HPV vaccine, and the shingles vaccine will soon contribute new doses

平安證券Apr 28 20:51

Zhifei Biotech (300122): Changes in agent product structure expected to release shingles vaccine

西南證券Apr 27 00:00

Zhifei Biotech (300122) Annual Report Review Report: Company fundamentals, high quality growth, high certainty, and shingles are expected to create a second growth curve

國盛證券Apr 25 00:00

Zhifei Biotech (300122) Company Comment: Proposed repurchase of 300 to 500 million yuan of company shares shows confidence in long-term development

國盛證券Feb 23 16:26

Zhifei Biotech (300122): “Double Improvement of Quality and Return” Program Boosts Confidence in Stable Development

中金公司Feb 19 18:26

Zhifei Biotech (300122) Company Review: Technology+Market Two-wheel Drive Prevention+Treatment Collaborative Development Promotes “Double Improvement of Quality and Return”

國盛證券Feb 18 20:11

Zhifei Biotech (300122): Clear “Double improvement in quality and return” is optimistic about the return of company value

德邦證券Feb 18 00:00

Zhifei Biotech (300122): Agent to restructure the shingles vaccine and plans to acquire a biopharmaceutical asset transformation platform company

浙商證券Dec 19, 2023 07:42

Zhifei Biotech (300122): Backed by two giants, MSD and GSK, rapid improvement in independent research and development

廣發證券Dec 1, 2023 00:00

Research Report Nuggets | Huaan Securities: Maintaining Zhifei Biotech's “Buy” Rating, Optimistic About High Annual Performance

Gelonghui FinanceNov 27, 2023 15:38

Zhifei Biotech (300122): Steady and far-reaching vaccine leaders embark on a new journey

華安證券Nov 27, 2023 07:42

Zhifei Biotech (300122): The proposed acquisition of 100% of Chenan Biotech's shares is expected to achieve valuation restructuring

國盛證券Nov 24, 2023 16:42